Pulmatrix and Cipla Announce First Patient Dosed in Phase 2 Trial Evaluating Pulmazole for Treatment of Allergic Bronchopulmonary Aspergillosis in Patients with Asthma

Stock Information for Pulmatrix Inc.

Loading

Please wait while we load your information from QuoteMedia.